摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

7-chloro-3-(2,4-dimethoxyphenyl)-1H-indazole | 680611-26-1

中文名称
——
中文别名
——
英文名称
7-chloro-3-(2,4-dimethoxyphenyl)-1H-indazole
英文别名
7-chloro-3-(2,4-dimethoxyphenyl)-2H-indazole
7-chloro-3-(2,4-dimethoxyphenyl)-1H-indazole化学式
CAS
680611-26-1
化学式
C15H13ClN2O2
mdl
——
分子量
288.733
InChiKey
HPXJHIIIUQVVIB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.8
  • 重原子数:
    20
  • 可旋转键数:
    3
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.13
  • 拓扑面积:
    47.1
  • 氢给体数:
    1
  • 氢受体数:
    3

反应信息

  • 作为产物:
    描述:
    (3-chloro-2-fluorophenyl)(2,4-dimethoxyphenyl)methanone一水合肼4-二甲氨基吡啶 作用下, 以to give the product (0.618 g) as a yellow solid的产率得到7-chloro-3-(2,4-dimethoxyphenyl)-1H-indazole
    参考文献:
    名称:
    Indazoles useful in treating cardiovascular diseases
    摘要:
    这项发明提供了I式或Ia式化合物:它们可用于治疗或抑制LXR介导的疾病。
    公开号:
    US20060030612A1
点击查看最新优质反应信息

文献信息

  • Substituted 4-(indazol-3-yl)phenols
    申请人:Wyeth
    公开号:US20040167127A1
    公开(公告)日:2004-08-26
    This invention provides compound of formulae I or II having the structure 1 wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , and R 10 are as defined in the specification or a pharmaceutically acceptable salt thereof which are useful for the treatment of the inflammatory component of diseases and are particularly useful in treating atherosclerosis, myocardial infarction, congestive heart failure, inflammatory bowel disease, arthritis, type II diabetes, and autoimmune diseases such as multiple sclerosis and rheumatiod arthritis.
    本发明提供了式I或式II的化合物,其结构为1,其中R1、R2、R3、R4、R5、R6、R7、R8、R9和R10如规范中所定义,或其药学上可接受的盐,其对于疾病的炎症成分具有治疗作用,尤其是在治疗动脉粥样硬化、心肌梗死、充血性心力衰竭、炎症性肠病、关节炎、2型糖尿病以及自身免疫性疾病如多发性硬化和类风湿性关节炎方面特别有用。
  • Substituted 4-(Indazol-3-yl)phenols
    申请人:Steffan J. Robert
    公开号:US20070225349A1
    公开(公告)日:2007-09-27
    This invention provides compound of formulae I or II having the structure wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , and R 10 are as defined in the specification or a pharmaceutically acceptable salt thereof which are useful for the treatment of the inflammatory component of diseases and are particularly useful in treating atherosclerosis, myocardial infarction, congestive heart failure, inflammatory bowel disease, arthritis, type II diabetes, and autoimmune diseases such as multiple sclerosis and rheumatiod arthritis.
    该发明提供了式I或II的化合物,其结构为: 其中R1、R2、R3、R4、R5、R6、R7、R8、R9和R10如规范中所定义,或其药学上可接受的盐,用于治疗疾病的炎症成分,特别适用于治疗动脉硬化、心肌梗塞、充血性心力衰竭、炎症性肠病、关节炎、II型糖尿病以及多发性硬化和风湿性关节炎等自身免疫疾病。
  • Indazoles
    申请人:Wyeth
    公开号:US07592363B2
    公开(公告)日:2009-09-22
    This invention provides compounds of Formula (I) or (Ia): that are useful in the treatment or inhibition of LXR mediated diseases.
    该发明提供了公式(I)或(Ia)的化合物:它们在治疗或抑制LXR介导的疾病方面是有用的。
  • 3-((hetero)aryl)-indazoles as Liver X receptor (LXR) and Th-1 inhibitors for the treatment of cardiovascular diseases
    申请人:Wyeth LLC
    公开号:EP2295429A1
    公开(公告)日:2011-03-16
    This invention provides compounds of Formula (Ia): wherein: R1 has various meanings including C1-6 alkyl, CN, CO2R5, C(O)R5, C2-6 alkenyl, C3-8 cycloalkenyl, C2-6 alkynyl, NR5R6, C(O)NR5R6, phenyl, thiophene, C1-3 alkoxy, halogen and S(O)kR5; R2 is heteroaryl, substituted with YD; or R2 is phenyl substituted with up to four substituents YD; R20 is H or C1-3 alkyl; and R4 is H, halogen, methyl or methoxy; and pharmaceutically acceptable salts thereof. The compounds and salts are useful in the treatment or inhibition of Liver X Receptor (LXR) mediated diseases.
    本发明提供了式 (Ia) 的化合物: 其中 R1具有各种含义,包括C1-6烷基、CN、CO2R5、C(O)R5、C2-6烯基、C3-8环烯基、C2-6炔基、NR5R6、C(O)NR5R6、苯基、噻吩、C1-3烷氧基、卤素和S(O)kR5; R2 是被 YD 取代的杂芳基;或 R2 是被最多四个 YD 取代基取代的苯基; R20 是 H 或 C1-3 烷基;以及 R4 是 H、卤素、甲基或甲氧基; 及其药学上可接受的盐类。 这些化合物和盐可用于治疗或抑制肝 X 受体(LXR)介导的疾病。
  • SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES
    申请人:Wyeth
    公开号:EP1542976B1
    公开(公告)日:2009-02-04
查看更多